Company Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-14 pm EDT 5-day change 1st Jan Change
105.6 USD -0.79% Intraday chart for Blueprint Medicines Corporation +2.14% +14.43%

Business Summary

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Number of employees: 645

Sales per Business

USD in Million2022Weight2023Weight Delta
Precision Therapies
100.0 %
204 100.0 % 249 100.0 % +22.22%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
91.1 %
190 93.3 % 227 91.1 % +19.38%
Rest of World
8.9 %
14 6.7 % 22 8.9 % +61.52%

Managers

Managers TitleAgeSince
Chief Executive Officer 48 16-01-04
Founder 52 08-09-30
Director of Finance/CFO 52 14-08-31
Chairman 52 14-07-23
Chief Tech/Sci/R&D Officer 61 20-02-29
Chief Tech/Sci/R&D Officer 58 20-04-30
Chief Tech/Sci/R&D Officer 53 21-05-18
Chief Operating Officer 48 18-10-28
Chief Tech/Sci/R&D Officer 61 17-10-09
Compliance Officer 56 16-09-05

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 16-04-13
Founder 52 08-09-30
Director/Board Member 58 16-02-03
Founder 67 08-09-30
Director/Board Member 69 15-06-24
Director/Board Member 45 21-12-07
Chairman 52 14-07-23
Chief Executive Officer 48 16-01-04
Director/Board Member 54 22-06-22
Director/Board Member 57 23-01-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,616,902 62,062,451 ( 99.11 %) 0 99.11 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.08 %
6,309,977 10.08 % 666 M $
T. Rowe Price International Ltd.
9.983 %
6,250,823 9.983 % 660 M $
BlackRock Advisors LLC
9.261 %
5,799,233 9.261 % 612 M $
Fidelity Management & Research Co. LLC
8.256 %
5,169,517 8.256 % 546 M $
Wellington Management Co. LLP
6.668 %
4,175,152 6.668 % 441 M $
Rock Springs Capital Management LP
3.990 %
2,498,448 3.990 % 264 M $
2,192,702 3.502 % 231 M $
Pictet Asset Management Holding SA
2.978 %
1,864,538 2.978 % 197 M $
William Blair Investment Management LLC
2.728 %
1,708,048 2.728 % 180 M $
Geode Capital Management LLC
2.190 %
1,371,127 2.190 % 145 M $

Company contact information

Blueprint Medicines Corp.

45 Sidney Street

02139, Cambridge

+617 374 7580

http://www.blueprintmedicines.com
address Blueprint Medicines Corporation(BPMC)
  1. Stock Market
  2. Equities
  3. BPMC Stock
  4. Company Blueprint Medicines Corporation